Review



bv2 murine mg  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ATCC bv2 murine mg
    MG corroborate with KRAS-G12V-EC to promote the loss of EC integrity in vitro. (a) A schematic diagram of the experiment. KRAS-G12V-EC-CM (conditioned medium) was added to <t>BV2-MG</t> and incubated for 48 h ( for b ), and then BV2-CM was transferred to control EC for 48 h ( for c ), or KRAS-G12V-EC-CM was added to control EC for 48 hours ( for d ); (b) Bar graphs showing increased mRNA levels in inflammatory cytokines (IL-6, IL-1β), proteolytic enzymes (MMP-9), and the MG-survival factor (CSF1R) in KRAS-G12V-EC-CM treated BV2-MG; (c) Bar graphs showing decreased mRNA levels of junction markers, CDH5 and TJP1, in EC after 2 days of incubation with BV2-CM, while OCLN and CLDN5 did not change; (d) Bar graphs showing non-significant changes in mRNA levels of junction markers in EC after 2 days of incubation with KRAS-G12V-EC-CM. Unpaired t -test. ns indicates no significant differences. All experiments are repeated three times. * p < 0.05. ** p < 0.01.
    Bv2 Murine Mg, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 54 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bv2 murine mg/product/ATCC
    Average 94 stars, based on 54 article reviews
    bv2 murine mg - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "Mutant KRAS in brain endothelial cells promotes vascular inflammation and impairs vascular integrity in brain arteriovenous malformation"

    Article Title: Mutant KRAS in brain endothelial cells promotes vascular inflammation and impairs vascular integrity in brain arteriovenous malformation

    Journal: Journal of Cerebral Blood Flow & Metabolism

    doi: 10.1177/0271678X261421424

    MG corroborate with KRAS-G12V-EC to promote the loss of EC integrity in vitro. (a) A schematic diagram of the experiment. KRAS-G12V-EC-CM (conditioned medium) was added to BV2-MG and incubated for 48 h ( for b ), and then BV2-CM was transferred to control EC for 48 h ( for c ), or KRAS-G12V-EC-CM was added to control EC for 48 hours ( for d ); (b) Bar graphs showing increased mRNA levels in inflammatory cytokines (IL-6, IL-1β), proteolytic enzymes (MMP-9), and the MG-survival factor (CSF1R) in KRAS-G12V-EC-CM treated BV2-MG; (c) Bar graphs showing decreased mRNA levels of junction markers, CDH5 and TJP1, in EC after 2 days of incubation with BV2-CM, while OCLN and CLDN5 did not change; (d) Bar graphs showing non-significant changes in mRNA levels of junction markers in EC after 2 days of incubation with KRAS-G12V-EC-CM. Unpaired t -test. ns indicates no significant differences. All experiments are repeated three times. * p < 0.05. ** p < 0.01.
    Figure Legend Snippet: MG corroborate with KRAS-G12V-EC to promote the loss of EC integrity in vitro. (a) A schematic diagram of the experiment. KRAS-G12V-EC-CM (conditioned medium) was added to BV2-MG and incubated for 48 h ( for b ), and then BV2-CM was transferred to control EC for 48 h ( for c ), or KRAS-G12V-EC-CM was added to control EC for 48 hours ( for d ); (b) Bar graphs showing increased mRNA levels in inflammatory cytokines (IL-6, IL-1β), proteolytic enzymes (MMP-9), and the MG-survival factor (CSF1R) in KRAS-G12V-EC-CM treated BV2-MG; (c) Bar graphs showing decreased mRNA levels of junction markers, CDH5 and TJP1, in EC after 2 days of incubation with BV2-CM, while OCLN and CLDN5 did not change; (d) Bar graphs showing non-significant changes in mRNA levels of junction markers in EC after 2 days of incubation with KRAS-G12V-EC-CM. Unpaired t -test. ns indicates no significant differences. All experiments are repeated three times. * p < 0.05. ** p < 0.01.

    Techniques Used: In Vitro, Incubation, Control

    Minocycline attenuates KRAS-G12V-EC-induced MG migration in vitro. (a) BV2-MG transmigration activities were tested using a transwell insert (please see the detailed procedure in the section “Materials and methods”); (b) Immunofluorescence staining showing accelerated BV2-MG migration 12 h later by KRAS mutation in ECs. Scale bars = 20 μm; (c, d) Minocycline (100 μM) or PBS was treated on ECs 1 day post-mutant KRAS (or GFP) transfection to test the effects on BV2-MG migration. Bar graphs showing migrated Iba1 + MG in the bottom well at 4 days post-minocycline treatment, compared to PBS. ANOVA with Turkey’s multiple comparisons test. Scale bars = 100 μm. *** p < 0.001.
    Figure Legend Snippet: Minocycline attenuates KRAS-G12V-EC-induced MG migration in vitro. (a) BV2-MG transmigration activities were tested using a transwell insert (please see the detailed procedure in the section “Materials and methods”); (b) Immunofluorescence staining showing accelerated BV2-MG migration 12 h later by KRAS mutation in ECs. Scale bars = 20 μm; (c, d) Minocycline (100 μM) or PBS was treated on ECs 1 day post-mutant KRAS (or GFP) transfection to test the effects on BV2-MG migration. Bar graphs showing migrated Iba1 + MG in the bottom well at 4 days post-minocycline treatment, compared to PBS. ANOVA with Turkey’s multiple comparisons test. Scale bars = 100 μm. *** p < 0.001.

    Techniques Used: Migration, In Vitro, Transmigration Assay, Immunofluorescence, Staining, Mutagenesis, Transfection



    Similar Products

    bv2 murine mg  (ATCC)
    94
    ATCC bv2 murine mg
    MG corroborate with KRAS-G12V-EC to promote the loss of EC integrity in vitro. (a) A schematic diagram of the experiment. KRAS-G12V-EC-CM (conditioned medium) was added to <t>BV2-MG</t> and incubated for 48 h ( for b ), and then BV2-CM was transferred to control EC for 48 h ( for c ), or KRAS-G12V-EC-CM was added to control EC for 48 hours ( for d ); (b) Bar graphs showing increased mRNA levels in inflammatory cytokines (IL-6, IL-1β), proteolytic enzymes (MMP-9), and the MG-survival factor (CSF1R) in KRAS-G12V-EC-CM treated BV2-MG; (c) Bar graphs showing decreased mRNA levels of junction markers, CDH5 and TJP1, in EC after 2 days of incubation with BV2-CM, while OCLN and CLDN5 did not change; (d) Bar graphs showing non-significant changes in mRNA levels of junction markers in EC after 2 days of incubation with KRAS-G12V-EC-CM. Unpaired t -test. ns indicates no significant differences. All experiments are repeated three times. * p < 0.05. ** p < 0.01.
    Bv2 Murine Mg, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bv2 murine mg/product/ATCC
    Average 94 stars, based on 1 article reviews
    bv2 murine mg - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    MG corroborate with KRAS-G12V-EC to promote the loss of EC integrity in vitro. (a) A schematic diagram of the experiment. KRAS-G12V-EC-CM (conditioned medium) was added to BV2-MG and incubated for 48 h ( for b ), and then BV2-CM was transferred to control EC for 48 h ( for c ), or KRAS-G12V-EC-CM was added to control EC for 48 hours ( for d ); (b) Bar graphs showing increased mRNA levels in inflammatory cytokines (IL-6, IL-1β), proteolytic enzymes (MMP-9), and the MG-survival factor (CSF1R) in KRAS-G12V-EC-CM treated BV2-MG; (c) Bar graphs showing decreased mRNA levels of junction markers, CDH5 and TJP1, in EC after 2 days of incubation with BV2-CM, while OCLN and CLDN5 did not change; (d) Bar graphs showing non-significant changes in mRNA levels of junction markers in EC after 2 days of incubation with KRAS-G12V-EC-CM. Unpaired t -test. ns indicates no significant differences. All experiments are repeated three times. * p < 0.05. ** p < 0.01.

    Journal: Journal of Cerebral Blood Flow & Metabolism

    Article Title: Mutant KRAS in brain endothelial cells promotes vascular inflammation and impairs vascular integrity in brain arteriovenous malformation

    doi: 10.1177/0271678X261421424

    Figure Lengend Snippet: MG corroborate with KRAS-G12V-EC to promote the loss of EC integrity in vitro. (a) A schematic diagram of the experiment. KRAS-G12V-EC-CM (conditioned medium) was added to BV2-MG and incubated for 48 h ( for b ), and then BV2-CM was transferred to control EC for 48 h ( for c ), or KRAS-G12V-EC-CM was added to control EC for 48 hours ( for d ); (b) Bar graphs showing increased mRNA levels in inflammatory cytokines (IL-6, IL-1β), proteolytic enzymes (MMP-9), and the MG-survival factor (CSF1R) in KRAS-G12V-EC-CM treated BV2-MG; (c) Bar graphs showing decreased mRNA levels of junction markers, CDH5 and TJP1, in EC after 2 days of incubation with BV2-CM, while OCLN and CLDN5 did not change; (d) Bar graphs showing non-significant changes in mRNA levels of junction markers in EC after 2 days of incubation with KRAS-G12V-EC-CM. Unpaired t -test. ns indicates no significant differences. All experiments are repeated three times. * p < 0.05. ** p < 0.01.

    Article Snippet: BV2 murine MG (CRL-2468; ATCC, Manassas, VA, USA) were cultured at passage four with a medium containing high glucose (CM002-050; GenDEPOT, Katy, TX, USA), 10% fetal bovine serum (F0901-050; GenDEPOT), and penicillin-streptomycin (CA005; GenDEPOT) at 37°C in a 5% CO 2 humidified incubator.

    Techniques: In Vitro, Incubation, Control

    Minocycline attenuates KRAS-G12V-EC-induced MG migration in vitro. (a) BV2-MG transmigration activities were tested using a transwell insert (please see the detailed procedure in the section “Materials and methods”); (b) Immunofluorescence staining showing accelerated BV2-MG migration 12 h later by KRAS mutation in ECs. Scale bars = 20 μm; (c, d) Minocycline (100 μM) or PBS was treated on ECs 1 day post-mutant KRAS (or GFP) transfection to test the effects on BV2-MG migration. Bar graphs showing migrated Iba1 + MG in the bottom well at 4 days post-minocycline treatment, compared to PBS. ANOVA with Turkey’s multiple comparisons test. Scale bars = 100 μm. *** p < 0.001.

    Journal: Journal of Cerebral Blood Flow & Metabolism

    Article Title: Mutant KRAS in brain endothelial cells promotes vascular inflammation and impairs vascular integrity in brain arteriovenous malformation

    doi: 10.1177/0271678X261421424

    Figure Lengend Snippet: Minocycline attenuates KRAS-G12V-EC-induced MG migration in vitro. (a) BV2-MG transmigration activities were tested using a transwell insert (please see the detailed procedure in the section “Materials and methods”); (b) Immunofluorescence staining showing accelerated BV2-MG migration 12 h later by KRAS mutation in ECs. Scale bars = 20 μm; (c, d) Minocycline (100 μM) or PBS was treated on ECs 1 day post-mutant KRAS (or GFP) transfection to test the effects on BV2-MG migration. Bar graphs showing migrated Iba1 + MG in the bottom well at 4 days post-minocycline treatment, compared to PBS. ANOVA with Turkey’s multiple comparisons test. Scale bars = 100 μm. *** p < 0.001.

    Article Snippet: BV2 murine MG (CRL-2468; ATCC, Manassas, VA, USA) were cultured at passage four with a medium containing high glucose (CM002-050; GenDEPOT, Katy, TX, USA), 10% fetal bovine serum (F0901-050; GenDEPOT), and penicillin-streptomycin (CA005; GenDEPOT) at 37°C in a 5% CO 2 humidified incubator.

    Techniques: Migration, In Vitro, Transmigration Assay, Immunofluorescence, Staining, Mutagenesis, Transfection